A Phase 2 interventional study of Obicetrapib and Placebo in Dyslipidemia, Hypercholesterolemia and High Cholesterol, sponsored by NewAmsterdam Pharma. Completed at 10 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-29.
Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Hypercholesterolemia with a site in Japan — 2 open to participants now, 5 under way, 3 of them phase 3. Hypercholesterolemia · Japan.
Among the 53 studies in Hypercholesterolemia with a site in Japan, this one is the 41st largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2022, is one of 10 in phase 2, and was the 47th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →2 of the 53 studies in Hypercholesterolemia with a site in Japan are open now. Recruiting first, the newest first:
Kowa Company, Ltd. · Sites in Japan
Ages 18+
Stephen Nicholls · Sites in Japan, Australia, China and 6 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 22 · Phase 4 12
First in 2004; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 259 across the 50 interventional studies, 6,000 across the 3 observational. Of the 46 that completed or were terminated, 30 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 53 have an industry lead sponsor. The 10 most frequent:
NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
NewAmsterdam Pharma has 7 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypercholesterolemia with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
| NCT07634484Kowa Company, Ltd.A Post-Marketing Clinical Trial of Pemafibrate in Patients with Hypercholesterolemia and Inadequate Response to Statins | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Hypercholesterolemia with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy in Japanese patients. The screening period for this study will take up to 2-weeks. Afterwards, patients will be randomized to placebo, 2.5 mg obicetrapib, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period. After the treatment period, patients will continue for a 4-week safety follow-up visit.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 102 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-daily placebo
Drug: Placebo
once-daily Obicetrapib
Drug: Obicetrapib
once-daily Obicetrapib
Drug: Obicetrapib
once-daily Obicetrapib
Drug: Obicetrapib
tablet
Also known as: CETP inhibitor
No active ingredient
Also known as: placebo tablet
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).
Time frame: 8 Weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
Median percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).
Time frame: 8 Weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald]
LS Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).
Time frame: 8 Weeks
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
Time frame: 8 Weeks
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC)
Time frame: 8 Weeks
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC]
Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
Time frame: 8 Weeks
Mean Percent Change in Apolipoprotein B (ApoB)
Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8 Weeks
Median Percent Change in Apolipoprotein B (ApoB)
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8 Weeks
LS Mean Percent Change in Apolipoprotein B (ApoB)
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8 Weeks
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8 weeks
Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8 Weeks
LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8 Weeks
Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8 weeks
Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
Time frame: 8 Weeks
LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C)
LS Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
Time frame: 8 Weeks
| Milestone | Placebo | Experimental 2.5 mg Obicetrapib | Experimental 5 mg Obicetrapib | Experimental 10 mg Obicetrapib |
|---|---|---|---|---|
| Started | 26 | 25 | 25 | 26 |
| Completed | 26 | 25 | 25 | 26 |
| Not completed | 0 | 0 | 0 | 0 |
Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | -0.78 ± 14.581 | -25.90 ± 21.259 | -33.78 ± 13.247 | -36.80 ± 25.727 |
Median percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | -0.89 (-38.6 to 27.8) | -24.81 (-66.0 to 17.7) | -31.94 (-56.8 to -2.9) | -45.80 (-73.0 to 45.5) |
LS Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥400 mg/dL or LDL-C ≤50 mg/dL; if TG ≥400 mg/dL or LDL-C ≤50 mg/dL, then LDL-C level was measured directly by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | -0.48 ± 3.766 | -26.32 ± 3.844 | -33.82 ± 3.838 | -36.60 ± 3.765 |
Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | 0.43 ± 15.456 | -26.10 ± 23.477 | -30.50 ± 14.959 | -36.29 ± 24.513 |
Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC)
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | 0.67 (-35.3 to 32.5) | -25.97 (-67.6 to 41.9) | -30.40 (-57.8 to -2.7) | -43.72 (-72.0 to 30.9) |
Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | 0.69 ± 3.928 | -26.51 ± 4.013 | -30.54 ± 4.002 | -36.12 ± 3.926 |
Mean percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Mean Percent Change in Apolipoprotein B (ApoB) | -1.23 ± 10.614 | -19.80 ± 15.363 | -24.48 ± 13.909 | -26.66 ± 15.0 |
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Median Percent Change in Apolipoprotein B (ApoB) | -0.36 (-26.1 to 21.7) | -22.50 (-45.6 to 12.7) | -21.43 (-53.4 to 1.0) | -29.67 (-56.4 to 9.5) |
Median percent change from baseline to Day 56 in apolipoprotein B (ApoB) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| LS Mean Percent Change in Apolipoprotein B (ApoB) | -1.42 ± 2.407 | -20.43 ± 2.457 | -23.87 ± 2.457 | -26.29 ± 2.408 |
Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | -1.80 ± 12.328 | -25.42 ± 19.280 | -30.38 ± 13.839 | -30.25 ± 23.318 |
Median percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Median Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | -0.37 (-33.3 to 24.2) | -23.74 (-62.4 to 15.6) | -29.82 (-52.8 to 1.3) | -36.96 (-66.3 to 35.8) |
LS Mean percent change from baseline to Day 56 in non-high-density lipoprotein cholesterol (non-HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| LS Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | -1.72 ± 3.395 | -25.66 ± 3.463 | -30.11 ± 3.463 | -30.28 ± 3.395 |
Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) | 5.57 ± 13.271 | 134.75 ± 56.543 | 153.16 ± 46.879 | 158.75 ± 43.171 |
Median percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| Median Percent Change in High-density Lipoprotein Cholesterol (HDL-C) | 5.22 (-20.7 to 33.3) | 114.29 (57.3 to 307.0) | 144.44 (74.1 to 255.2) | 158.90 (76.6 to 281.6) |
LS Mean percent change from baseline to Day 56 in High-density lipoprotein cholesterol (HDL-C) (mg/dL) for each obicetrapib group compared with the placebo group.
| percent change from baseline | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib |
|---|---|---|---|---|
| LS Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) | 3.90 ± 7.141 | 137.00 ± 7.284 | 151.30 ± 7.282 | 159.87 ± 7.139 |
Collected over From first dose of study drug through Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/26 (0%) | 0/26 (0%) | 15/26 (57.7%) |
| Experimental 2.5 mg Obicetrapib | 0/25 (0%) | 0/25 (0%) | 9/25 (36%) |
| Experimental 5 mg Obicetrapib | 0/25 (0%) | 1/25 (4%) | 7/25 (28%) |
| Experimental 10 mg Obicetrapib | 0/26 (0%) | 0/26 (0%) | 15/26 (57.7%) |
| Event | Placebo | Experimental 2.5 mg Obicetrapib | Experimental 5 mg Obicetrapib | Experimental 10 mg Obicetrapib |
|---|---|---|---|---|
| Angina pectorisCardiac disorders | 0/26 | 0/25 | 1/25 | 0/26 |
| Event | Placebo | Experimental 2.5 mg Obicetrapib | Experimental 5 mg Obicetrapib | Experimental 10 mg Obicetrapib |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/26 | 0/25 | 1/25 | 2/26 |
| Back painMusculoskeletal and connective tissue disorders | 3/26 | 0/25 | 0/25 | 2/26 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/26 | 2/25 | 0/25 | 1/26 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/26 | 2/25 | 0/25 | 1/26 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/26 | 0/25 | 0/25 | 0/26 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 0/26 | 0/25 | 0/25 | 2/26 |
| COVID-19Infections and infestations | 1/26 | 0/25 | 1/25 | 1/26 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/26 | 0/25 | 1/25 | 0/26 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/26 | 1/25 | 0/25 | 0/26 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/26 | 1/25 | 0/25 | 0/26 |
Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.
| Age, Continuous(years) | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib | Total |
|---|---|---|---|---|---|
| Mean | 63.3 ± 9.44 | 65.8 ± 8.09 | 67.8 ± 9.46 | 62.5 ± 9.90 | 64.8 ± 9.36 |
| Sex: Female, Male(Participants) | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib | Total |
|---|---|---|---|---|---|
| Female | 6 | 10 | 6 | 7 | 29 |
| Male | 20 | 15 | 19 | 19 | 73 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 26 | 25 | 25 | 26 | 102 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 26 | 25 | 25 | 26 | 102 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values(milligrams per deciliter (mg/dL)) | Placebo | 2.5 mg Obicetrapib | 5 mg Obicetrapib | 10 mg Obicetrapib | Total |
|---|---|---|---|---|---|
| Mean | 110.1 ± 37.13 | 102.2 ± 26.58 | 106.4 ± 27.54 | 109.1 ± 32.47 | 106.95 ± 30.93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Mar 2023, 8 months.
Results were first posted in Sep 2024, 1 year 6 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 8 months is below that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TA-8995
NewAmsterdam Pharma